Navigation Links
Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
Date:5/28/2008

SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced that a live audio webcast and accompanying slide presentation will be provided for its analyst and investor briefing event "Sequenom: The Future of Noninvasive Prenatal Diagnostics." Details of the event are as follows:

What: Sequenom: The Future of Noninvasive Prenatal Diagnostics

When: Tuesday, June 3, 2008 at 6:00 p.m. Pacific time

Where: http://www.sequenom.com

Agenda:

Hosted by:

Harry Stylli, Ph.D., Chief Executive Officer of Sequenom, Inc.

Presenters:

Jacob Canick, Ph.D., Professor of Pathology and Laboratory Medicine

Brown University Medical School

"Methods for screening pregnancies for Down syndrome"

Allan T. Bombard, MD, FACOG, FACS, FACMG, Chief Medical Officer, Sharp

Mary Birch Hospital; Adjunct Professor, Obstetrics and Gynecology/SUNY

Downstate Medical Center; Clinical Professor, Albert Einstein College of

Medicine

"Current clinical practice for Down syndrome screening and diagnosis"

Betty Dragon, Ph.D., Senior Vice President, Research & Development of

Sequenom, Inc.

"Sequenom's SEQureDx: A noninvasive prenatal diagnostic test for Down

syndrome. Technical Achievements, Milestones and Future Challenges"

Dennis Lo, Consultant to Sequenom, Inc.

"The future of prenatal diagnosis: Progress through fetal nucleic acids"

How: Live over the Internet - Simply log on to the web at the address

above. Presentation will be archived.

Contact: Lippert/Heilshorn & Associates

Jody Cain (jcain@lhai.com)

310-691-7100

About Sequenom

Sequenom is committed to providing the best genetic analysis products for research and the molecular diagnostic markets. The Company makes available superior solutions for genomic science in biomedical research, livestock and agricultural applications and molecular medicine, as well as for various diagnostic markets, including noninvasive prenatal testing, oncology and infectious diseases. Sequenom's proprietary MassARRAY(R) system delivers reliable and specific data from complex biological samples and from genetic target materials available only in trace amounts.

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free from http://www.microsoft.com and at least a 56Kbps connection to the Internet. If you experience problems listening to the webcast, send an E-mail to: webcast@multivu.com.


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
2. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
3. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
4. CorVel Corporation Announces Earnings Release Webcast
5. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
6. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. Quest Diagnostics Announces Annual Shareholders Meeting Webcast
10. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
11. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):